|
Multimedia
Images, audio, and video related to cancer research
Calendar
Meetings, seminars, and press conferences focused on cancer research
Resources
Information on cancer types, treatment, prevention, and more
 Sponsored by:
The Cancer News Portal is supported by the National Cancer Institute of the National Institutes of Health. Additional information on cancer research, prevention, and treatment is available at www.cancer.gov |
Breaking News
Key: Meeting
Showing releases 151-175 out of 1124. << < 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 > >>
Public Release: 9-Nov-2012
 Mayo Clinic ProceedingsMinimally invasive lymph node dissection in breast cancer has advantages over conventional surgery Axillary lymph node dissection is done in conjunction with lumpectomy or mastectomy to determine if breast cancer has spread to the adjoining lymph nodes. The conventional surgical approach leaves a surgical scar that is unattractive and can restrict range of motion in the shoulder joint. Also, squeezing and pulling the tumor during the breast operation can stimulate tumor cell metastases. A new study in Mayo Clinic Proceedings reports that an endoscopic technique, mastoscopic axillary lymph node dissection, can reduce these complications. Contact: Rachael Zaleski
Public Release: 9-Nov-2012
Breast Cancer Research and TreatmentHigh-quality personal relationships improve survival in women with breast cancer The quality of a woman's social networks--the personal relationships that surround an individual--appears to be just as important as the size of her networks in predicting breast cancer survival, Kaiser Permanente scientists report in the current issue of Breast Cancer Research and Treatment. 
NIH/National Cancer Institute, Molecular Profiles and Lifestyle Factors in Breast Cancer Prognosis
Contact: Catherine Hylas Saunders
Public Release: 8-Nov-2012
Environmental Health PerspectivesChernobyl cleanup workers had significantly increased risk of leukemia A 20-year study following 110,645 workers who helped clean up after the 1986 Chernobyl nuclear power plant accident in the former Soviet territory of Ukraine shows that the workers share a significant increased risk of developing leukemia. The results may help scientists better define cancer risk associated with low doses of radiation from medical diagnostic radiation procedures such as computed tomography scans and other sources.
NIH/National Cancer Institute
Contact: Jason Socrates Bardi
Public Release: 8-Nov-2012
Current BiologyUMass Amherst cell biologists identify new protein key to asymmetric cell division Recently biologists at the University of Massachusetts Amherst led by Wei-lih Lee have identified a new molecular player in asymmetric cell division, a regulatory protein named She1 whose role in chromosome- and spindle positioning wasn't known before. Asymmetric cell division is important in the self-renewal of stem cells and because it ensures that daughter cells have different fates and functions.
NIH/National Institute of General Medical Sciences, American Heart Association
Contact: Janet Lathrop
Public Release: 8-Nov-2012
24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsFirst trial in humans of 'minicells': A completely new way of delivering anti-cancer drugs A completely new way of delivering anti-cancer drugs to tumours, using 'minicells' derived from bacteria, has been tested for the first time in humans and found to be safe, well-tolerated and even induced stable disease in patients with advanced, incurable cancers with no treatment options remaining. The research is presented at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.
EnGeneIC
Contact: Emma Mason
Public Release: 8-Nov-2012
24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsMesothelioma drug slows disease progression in patients with an inactive NF2 gene Preliminary findings from the first trial of a new drug for patients with mesothelioma show that it has some success in preventing the spread of the deadly disease in patients lacking an active tumour suppressor gene called NF2. The study is presented at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.
GlaxoSmithKline
Contact: Emma Mason
Public Release: 8-Nov-2012
Journal of Clinical OncologyOvarian cancer patients have lower mortality rates when treated at high-volume hospitals A study by researchers at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Medical Center, recently e-published ahead of print by the Journal of Clinical Oncology, suggests that women who have surgery for ovarian cancer at high-volume hospitals have superior outcomes than similar patients at low-volume hospitals.
NIH/National Cancer Institute
Contact: CUMC Communications
Public Release: 8-Nov-2012
American Journal of EpidemiologyRethinking body mass index for assessing cancer risk A study by researchers at Albert Einstein College of Medicine of Yeshiva University suggests that body mass index -- the most commonly used weight-for-height formula for estimating fatness -- may not be the best measure for estimating disease risk, and particularly the risk of certain types of cancer. The study was published today in the online edition of the American Journal of Epidemiology.
Albert Einstein College of Medicine
Contact: Kim Newman
Public Release: 8-Nov-2012
ScienceEven yeast mothers sacrifice all for their babies A mother's willingness to sacrifice her own health and safety for the sake of her children is a common narrative across cultures – and by no means unique to humans alone. Female polar bears starve, dolphin mothers stop sleeping and some spider moms give themselves as lunch for their crawly babies' first meal. Contact: Jason Socrates Bardi
Public Release: 8-Nov-2012
24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsMolecular 'portraits' of tumors match patients with trials in everyday clinical practice Researchers in France are taking advantage of the progress in genetic and molecular profiling to analyse the make-up of individual cancer patients' tumours and, using this information, assign them to particular treatments and phase I clinical trials -- an approach that could become part of everyday clinical practice. The research is presented at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland. Contact: Emma Mason
Public Release: 7-Nov-2012
24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsNew targeted therapy for advanced prostate cancer shows anti-tumor activity in clinical trials At the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland, researchers will report that a new drug that specifically targets a protein found on the surface of prostate cancer cells has performed well in a phase I clinical trial, and a phase II trial has started. The drug is being tested in patients with advanced, hormone-refractory prostate cancer, who usually die from the disease after 12 to 18 months, and who have few treatment options available.
Progenics Pharmaceuticals Inc.
Contact: Emma Mason
Public Release: 7-Nov-2012
Journal of the National Cancer InstituteHigher dietary glycemic load linked to worse colon cancer survival Researchers have identified a link between higher dietary glycemic load and total carbohydrate intake and increased risk of cancer recurrences or death among stage three colon cancer patients, a finding that suggests that diet and lifestyle modification can have a role in improving patient survival, according to a study published Nov. 7 in the Journal of the National Cancer Institute. Contact: Zachary Rathner
Public Release: 7-Nov-2012
Cancer Epidemiology, Biomarkers & PreventionInflammation marker linked to increased risk for death from cancer in Korean men High levels of the inflammation marker hs-CRP associated with increased risk for cancer death. No significant association was found in women. The relationship was more common in lean participants. Contact: Jeremy Moore
Public Release: 7-Nov-2012
24th EORTC /NCI/AACR Symposium: Molecular Targets and Cancer TherapeuticsResearchers develop non-invasive technique for predicting patients' response to chemotherapy Researchers have developed a non-invasive way of predicting how much of a cancer-killing drug is absorbed by a tumor. The preliminary study, which will be reported at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland, was conducted in lung cancer patients and it also revealed that less than one percent of the drug, docetaxel, is absorbed by the tumors.
Cancer Center Amsterdam
Contact: Emma Mason
Public Release: 7-Nov-2012
Science Translational MedicineSpread of human melanoma cells in mice correlates with clinical outcomes in patients UT Southwestern Medical Center scientists led by Dr. Sean Morrison, director of the Children's Medical Center Research Institute at UT Southwestern, have developed an innovative model for predicting the progression of skin cancer in patients. Contact: Jeff Carlson
Public Release: 7-Nov-2012
24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsPatients with aberrations in two genes respond better to drugs blocking a well-known cancer pathway Cancer patients with mutations or variations in two genes -- PIK3CA and PTEN -- who have failed to respond to several, standard treatments, respond significantly better to anti-cancer drugs that inhibit these genes' pathways of action, according to research presented at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.
NIH/National Center for Research Resources
Contact: Emma Mason
Public Release: 7-Nov-2012
ThyroidFirst comprehensive guidelines for managing anaplastic thyroid cancer published in Thyroid journal Naplastic thyroid cancer is a rare form of thyroid tumor, but it is also the most deadly. Newly developed evidence-based recommendations for the diagnosis, treatment, and long-term monitoring and follow-up care of patients with this extremely aggressive form of thyroid cancer are published in Thyroid. Contact: Vicki Cohn
Public Release: 7-Nov-2012
International Journal of CancerResearchers explore connection between popular pain relievers, bladder cancer Dartmouth researchers have found that duration of ibuprofen use was associated with a reduced risk of bladder cancer in patients in northern New England, which has a high mortality rate of this disease.
National Institutes of Health
Contact: Donna Dubuc
Public Release: 7-Nov-2012
Journal of National Cancer InstituteStarchy, high carbohydrate diet associated with recurrence of colon cancer Colon cancer survivors whose diet is heavy in complex sugars and carbohydrate-rich foods are far more likely to have a recurrence of the disease than are patients who eat a better balance of foods, a new study by Dana-Farber Cancer Institute researchers indicates.
NIH/National Cancer Institute, Pfizer Oncology
Contact: Anne Doerr
Public Release: 6-Nov-2012
24th EORTC /NCI/AACR Symposium: Molecular Targets and Cancer TherapeuticsNew monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial A newly developed antibody targeting a signalling pathway that is frequently active in solid tumors has shown encouraging signs of efficacy in its first trial in humans, researchers will report at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland, on Wednesday.
F. Hoffmann-La Roche, Inc.
Contact: Emma Mason
Public Release: 6-Nov-2012
24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsScientists test 5,000 combinations of 100 existing cancer drugs to find more effective treatments Scientists have tested all possible pairings of the 100 cancer drugs in order to discover whether there are any combinations not tried previously that are effective in certain cancers. Dr Susan Holbeck will tell the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland, that she has completed testing the 100 drugs, with 300,000 experiments to test the 5,000 possible drug combinations in a panel of 60 cell lines developed by the National Cancer Institute.
NIH/National Cancer Institute
Contact: Emma Mason
Public Release: 6-Nov-2012
American Heart Association 2012 Scientific Sessions Temple researchers show targeted cancer drug may stunt heart's ability to repair itself Scientists have shown how a "targeted" cancer drug may affect the heart. Studying mice with the equivalent of a heart attack, researchers found that the cancer drug sorafenib – which inhibits tyrosine kinase receptors – can interfere with heart stem cell activity, affecting the heart's ability to repair itself. The findings suggest that sorafenib and similar drugs may raise the risk for heart attack for some cancer patients with heart disease.
National Institutes of Health, American Heart Association
Contact: Steven Benowitz
Public Release: 6-Nov-2012
Circulation'Smoke-free' laws lead to fewer hospitalizations and deaths Laws that end smoking at work and other public places result in significantly fewer hospitalizations for heart attacks, strokes, asthma and other respiratory conditions, a new UCSF analysis has found. Contact: Elizabeth Fernandez
Public Release: 6-Nov-2012
PLOS ONEBreast cancer drug could halt other tumors A drug commonly used in treating breast cancer could have far wider benefits, offering a new way of preventing cancers spreading through the body, according to a University of Leeds-led study.
Wellcome Trust
Contact: Chris Bunting
Public Release: 6-Nov-2012
24th EORTC /NCI/AACR Symposium: Molecular Targets and Cancer TherapeuticsTaiho Pharmaceutical unveils data on 8 novel anticancer compounds Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil Chemotherapeutic treatment, is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies. The data are being presented during the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics from Nov. 6 – 9, 2012 in Dublin, Ireland. Contact: Kerry Sinclair
Showing releases 151-175 out of 1124. << < 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 > >>
|
Search News Releases
|
|||||||||||||||||||||||||
 |
||||
|
|
 |
|